Business description
Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 mitogen-activated protein kinase inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company was founded in 2017 and is based in Basel, Switzerland.
Management board & Supervisory board
| CEO |
| Dr. Marian Borovsky |
| Management board |
| Dr. Marian Borovsky, Günter Graubach, Dr. Silvio Inderbitzin, Dr. Roland Rutschmann |
| Supervisory board |
| - |
Company data
| Name: |
Kinarus Therapeutics Holding AG |
| Address: |
Technologiepark Basel Hochbergerstrasse 60C,Basel |
| Phone: |
+41 61 633 29 71 |
| Fax: |
- |
| E-mail: |
info@kinarus.com
|
| Internet: |
https://www.kinarus.com/ |
| Industry: |
Healthcare |
| Sector: |
Medical Products |
| Sub sector: |
Advanced Medical Devices |
| End of financial year: |
12-31 |
| Free Float: |
86.69% |
| IPO date: |
2001-01-22 |
